Please assess the completion status of the following clinical trial:

Trial Title: Lidocaine Injection and Ischemic Compression on Chronic Pelvic Pain Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women with chronic diagnosis of pelvic pain;~2. Women in menacme;~3. Presence of the diagnostic criteria for abdominal myofascial syndrome;~4. Agreement with the Term of Free and Clarified Assent.~Exclusion Criteria:~1. Endometriosis, interstitial cystitis, syndrome of the irritable intestine or another illness that it justifies or it contributes for chronic pelvic pain;~2. Endometrioma or hernia evidenced to the ultrasound of the abdominal wall.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- lidocaine injection (Type: EXPERIMENTAL): Lidocaine injection. Women randomized for this treatment was submitted to 2 milliliters of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point.~Patients received lidocaine injections once a week for 4 weeks
- Ischemic compression (Type: EXPERIMENTAL): Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation (TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.

Based on this trial design, predict the completion outcome and termination type (if applicable).